Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02852-9 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Daisuke Kotani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. dkotani@east.ncc.go.jp. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Benzofurans, Quinazolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HUTCHMED.
Abstract (Originalsprache)
Background
In the phase 3 FRESCO-2 study, fruquintinib plus best supportive care (BSC) significantly improved overall survival (OS) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). We present the results of a FRESCO-2 post hoc subgroup analysis evaluating outcomes of patients enrolled in Japan.
Methods
In FRESCO-2, patients had previously received all standard chemotherapies, anti-VEGF and anti-EGFR therapies if indicated, and had progressed on, or were intolerant to trifluridine-tipiracil and/or regorafenib. Patients were randomized 2:1 to receive fruquintinib 5 mg or matching placebo by mouth once daily on days 1–21 in 28-day cycles, plus BSC. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and safety.
Results
Of the 56 patients enrolled in Japan, 40 (71.4%) and 16 (28.6%) were randomized to fruquintinib and placebo, respectively. OS was improved with fruquintinib versus placebo (median 6.9 vs. 5.6 months; hazard ratio [HR], 0.42; 95% confidence interval [CI] 0.19 − 0.92). PFS was also improved with fruquintinib versus placebo (median 3.6 vs. 1.8 months; HR, 0.27; 95% CI 0.13 − 0.56). The incidence of grade ≥ 3 treatment-emergent adverse events (TEAEs) with fruquintinib versus placebo was 71.8% versus 29.4%; the most common grade ≥ 3 TEAEs with fruquintinib were hypertension (23.1%) and palmar-plantar erythrodysesthesia (17.9%).
Conclusions
Fruquintinib improved OS and PFS versus placebo in FRESCO-2 patients enrolled in Japan and demonstrated a manageable safety profile. Results from the Japan subgroup were consistent with the global FRESCO-2 population, thus supporting fruquintinib as a novel treatment option for patients in Japan with refractory mCRC. Clinical trial details ClinicalTrials.gov; NCT04322539.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. dkotani@east.ncc.go.jp.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan.
- Department of Clinical Oncology, St Marianna University School of Medicine, Kanagawa, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Förderung
- HUTCHMED
Zitieren
APA
Kotani, D., Yoshino, T., Masuishi, T., Sunakawa, Y., Takashima, A., Yamazaki, K., Kawakami, H., Nishina, T., Komatsu, Y., Esaki, T., Eng, C., Ukrainskyj, S., Pallai, R., Nanda, S., Yang, Z., Schelman, W., Kania, M., & Satoh, T. (2025). Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02852-9
Vancouver
Kotani D, Yoshino T, Masuishi T, Sunakawa Y, Takashima A, Yamazaki K, et al. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02852-9
BibTeX
@article{Kotani2025,
author = {Kotani, Daisuke and Yoshino, Takayuki and Masuishi, Toshiki and Sunakawa, Yu and Takashima, Atsuo and Yamazaki, Kentaro and Kawakami, Hisato and Nishina, Tomohiro and Komatsu, Yoshito and Esaki, Taito and Eng, Cathy and Ukrainskyj, Stacey and Pallai, Rajash and Nanda, Shivani and Yang, Zhao and Schelman, William and Kania, Marek and Satoh, Taroh},
title = {Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02852-9}
}
EUVIMED